And while predicting Dendreon's stock price has been the most difficult aspect of this story, anyone following along with the Dendreon stock and option plays in our Biotech Stock Research Model Portfolio have banked significant returns …
NEW YORK (Reuters) - A lightening fast sell-off of shares of biotech company Dendreon last April is drawing scrutiny from U.S. securities regulators and the independent monitor assigned to keep tabs on those regulators, said people …
J.P. Morgan (NYSE: JPM) has a $46 price target on the shares. During the last 52 weeks, Dendreon's stock has traded from a low of $2.55 to a high of $33.85. There are few signs that the momentum in this name will not continue. If their …
That move prompted at least six brokerages to cut their rating on Dendreon s stock. The company has pointed to reimbursement concerns and delayed physician adoption as the primary reasons why Provenge s sales growth has …
The volatility of Dendreon's stock provides a fascinating insight into the allure of a new treatment modality, the bungles of the Provenge trials and the steely determination of the company to bring its first ever product to market. Dendreon's …
I talked to Greg Schiffman, Dendreon’s CFO, this morning on the company’s announcement that it would raise about $46 million, after fees, by selling some of its stock to an institutional investor. Below are some highlights of that interview.
Shares of Dendreon (Nasdaq: DNDN) are trading significantly higher ... But how much room is left to run in the stock? …
Many investors appear to be quite bearish on Dendreon Corporation (DNDN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 26.92% of the float is sold short, suggesting an extreme level of …
Companies whose shares are expected to trade actively in today’s session are KBR, Inc. (NYSE:KBR), Dendreon Corporation (NASDAQ:DNDN), Best Buy Co., Inc. (NYSE ... DNDN): The biotech stock has been heavily shorted for …
An analyst apologized to clients late Wednesday for his calls on troubled biotechnology company Dendreon Corp., as he moved his rating on the shares to hold from buy in the wake of the company lowering sales estimates for the coming …